> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Skyrizi Better Than Stelara: AbbVie Data
- URL: https://www.fdaweb.com/skyrizi-better-than-stelara-abbvie-data/
- Published: 2023-10-16T12:00:00.000Z
- Updated: 2026-09-14T14:13:26.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155574

AbbVie is reporting “positive results” from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of its Skyrizi (risankizumab) 600 mg intravenous \[IV\] drug compared to Janssen’s Stelara (ustekinumab) 600 mg IV in patients with moderately to severely active Crohn’s disease who have failed one or more anti-TNFs.

According to the company, Skyrizi met both primary endpoints of non-inferiority for clinical remission (Crohn's Disease Activity Index) at Week 24 and superiority of endoscopic remission at Week 48 versus Stelara. Skyrizi also showed superiority versus Stelar for all ranked secondary endpoints, including achievement of clinical remission at Week 48, achievement of endoscopic response at Week 48 and 24, achievement of steroid-free endoscopic remission at Week 48 and achievement of steroid-free clinical remission at Week 48\. “Safety results were consistent with the overall safety profile of risankizumab, with no new safety risks identified,” AbbVie says.